In a large CRC cohort, tumor-infiltrating IL17-producing cells have not worsened clinical outcome and recruit highly cytotoxic CCR5+CCR6+CD8+ T cells via the release of CCL5 and CCL20 [96]. Here, IL17A is linked to neoplasm.